All In Biotech

Drug Trial Radar · NCT04696731

Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

A Phase 1A/1B Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 With Cyclophosphamide/Fludarabine Lymphodepletion Alone or Including ALLO-647 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)

Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Feb 24, 2021

Primary completion

Jan 2030

Study completion Jan 2030

Sponsor

Lead sponsor
Allogene TherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1 dose escalation study using a 3+3 study design, followed by a phase 1b expansion study. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced or metastatic clear cell renal cell carcinoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, with or without ALLO-647 to define a Phase 2 dose.

Conditions

  • Advanced/Metastatic Clear Cell Renal Cell Carcinoma

Interventions

  • ALLO-316Genetic

    ALLO-316 is an allogeneic CAR T cell therapy targeting CD70

  • ALLO-647Biological

    ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen

  • FludarabineDrug

    Chemotherapy for lymphodepletion

  • CyclophosphamideDrug

    Chemotherapy for lymphodepletion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects experiencing Dose Limiting Toxicities at increasing doses of ALLO-316Time frame: 28 days
  2. Proportion of patients experiencing Dose Limiting Toxicity with ALLO-647 in combination with fludarabine/cyclophosphamide administered prior to ALLO-316Time frame: 33 days

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • UCLA Medical Center

    Los Angeles, California

  • UCSF Medical Center

    San Francisco, California

  • Yale School of Medicine

    New Haven, Connecticut

  • Georgetown University Hospital

    Washington D.C., District of Columbia

  • Moffitt Cancer Center

    Tampa, Florida

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Providence Portland Medical Center

    Portland, Oregon

  • MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.